Recent Multiple Myeloma News

Addition of Darzalex™ Improves Outcomes in Newly Diagnosed Multiple Myeloma (December 13, 2017)

The addition of Darzalex (daratumumab) to the standard treatment combination consisting of Velcade (bortezomib), melphalan, and prednisone (VMP) reduces disease progression or death by 50%, among patients... Continue Reading

Diagnosed with Multiple Myeloma: 10 Tips on How to Get The Most From Your Doctor (November 20, 2017)

1) Choose Your Doctor Carefully Hematologists and oncologists are the primary doctors involved with multiple myeloma and often work in collaboration with stem cell transplant physicians. Pick your primary... Continue Reading

FDA Adds Two Roche Multiple Myeloma Studies Evaluating Checkpoint Inhibitors to List of Partial Clinical Holds Over Safety Concerns (September 25, 2017)

Alarmed that an imbalance in deaths among patients taking a combination of Keytruda (pembrolizumab) with Celgene’s Pomalyst and Revlimid could represent a threat in that whole class of checkpoint comboinations,... Continue Reading

Four-Year Follow-up with Empliciti Plus Revlimid in Patients with Advanced Multiple Myeloma Shows Long-term Beneift (July 13, 2017)

Four-year follow-up data from the Phase 3 ELOQUENT-2 clinical trial in which Empliciti (elotuzumab) plus Revlimid (lenalidomide) continued to demonstrate effectiveness in patients with relapsed/refractory... Continue Reading

Revlimid Maintenance Therapy Related to More Secondary Primary Malignancies in Older Adults (April 25, 2017)

Results from a pivotal clinical trial have supported the use of Revlimid (lenalidomide) as maintenance therapy for patients multiple myeloma.  A new analysis from the trial just published in the Journal,... Continue Reading

FDA Expands Indication for Revlimid® as a Maintenance Treatment for Patients with Multiple Myeloma Following Autologous Stem Cell Transplant (March 28, 2017)

The U.S. Food and Drug Administration (FDA) expanded the existing indication for Revlimid® (lenalidomide) to include use for patients with multiple myeloma as maintenance therapy following autologous... Continue Reading

Kyprolis® Significantly Improves Overall Survival Compared To Velcade® In Relapsed Or Refractory Multiple Myeloma (March 22, 2017)

The ENDEAVOR trial results were updated at the 16th International Myeloma Workshop in New Delhi.  The trial demonstrated that Kyprolis (Carfilzomib) not only significantly extended progression-free survival... Continue Reading

Early Treatment in Smoldering Myeloma Improves Long-Term Outcomes (February 3, 2017)

Use of the treatment combination consisting of Revlimid (lenalidomide) plus dexamethasone during smoldering myeloma appears to significantly improve long-term outcomes for patients. These results were... Continue Reading

Velcade® Revlimid®/Dexamethasone New Standard of Care for Newly Diagnosed Multiple Myeloma (January 31, 2017)

The addition of the proteasome inhibitor Velcade® (bortezomib) to the treatment combination Revlimid® (lenalidomide) plus dexamethasone improves survival when used as initial therapy in multiple myeloma... Continue Reading

Scientific Highlights from American Society of Hematology Meeting (January 24, 2017)

About CAR-T CAR-T, or chimeric antigen receptor T-cells, is a new form of cancer immunotherapy in which a patient’s own T cells are removed and then engineered to identify and kill malignant multiple... Continue Reading

Next Page »